Literature DB >> 11334793

The effects of the Na(+)/Ca(++) exchange blocker on osmotic blood-brain barrier disruption.

A K Bhattacharjee1, T Nagashima, T Kondoh, N Tamaki.   

Abstract

Osmotic disruption of the blood-brain barrier (BBB) by mannitol is currently being used to enhance drug delivery in human brains. Despite clinical and experimental interest, to date the time course in the early phase of disruption has not been accurately identified. The mechanism in barrier closure also remains elusive. We first studied the rapid change in cerebrovascular permeability after BBB disruption in rats, and then demonstrated that the Na(+)/Ca(++) exchange blocker (KB-R7943) prolongs osmotic disruption. Osmotic BBB disruption was attained by using intra-arterial infusion of hypertonic mannitol in Sprague-Dawley (SD) rats. To measure the changes in cerebrovascular permeability, perfusate containing [14C]-sucrose was infused intra-arterially at different time points following osmotic stress. Cerebrovascular permeability was then measured with the in situ brain perfusion technique. This is the first in vivo study demonstrating that osmotic disruption is prolonged by the Na(+)/Ca(++) exchange blocker, which did not affect the peak level of BBB disruption. The exact time course of cerebrovascular reversibility was studied and the earliest BBB disruption was seen to occur 5 min after osmotic stress. Histopathological examination after osmotic disruption with the Na(+)/Ca(++) exchange blocker showed no neuronal damage in rat brains. Our findings represent important experimental information regarding pharmacological manipulation of BBB disruption. The possibility of prolonging the transient opening of the BBB has major clinical implications.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11334793     DOI: 10.1016/s0006-8993(01)02253-3

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  8 in total

Review 1.  Transporters at CNS barrier sites: obstacles or opportunities for drug delivery?

Authors:  Lucy Sanchez-Covarrubias; Lauren M Slosky; Brandon J Thompson; Thomas P Davis; Patrick T Ronaldson
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

2.  Impact of drug size on brain tumor and brain parenchyma delivery after a blood-brain barrier disruption.

Authors:  Marie Blanchette; Luc Tremblay; Martin Lepage; David Fortin
Journal:  J Cereb Blood Flow Metab       Date:  2014-02-12       Impact factor: 6.200

3.  Inconsistent blood brain barrier disruption by intraarterial mannitol in rabbits: implications for chemotherapy.

Authors:  Shailendra Joshi; Aysegul Ergin; Mei Wang; Roberto Reif; Jane Zhang; Jeffrey N Bruce; Irving J Bigio
Journal:  J Neurooncol       Date:  2010-12-12       Impact factor: 4.130

4.  Possible role of autoantibodies in the pathophysiology of GM2 gangliosidoses.

Authors:  Akira Yamaguchi; Kayoko Katsuyama; Kiyotaka Nagahama; Toshiyuki Takai; Ichiro Aoki; Shoji Yamanaka
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

Review 5.  Intracarotid delivery of drugs: the potential and the pitfalls.

Authors:  Shailendra Joshi; Phillip M Meyers; Eugene Ornstein
Journal:  Anesthesiology       Date:  2008-09       Impact factor: 7.892

6.  Glycosylation of dentin matrix protein 1 is a novel key element for astrocyte maturation and BBB integrity.

Authors:  Bo Jing; Chunxue Zhang; Xianjun Liu; Liqiang Zhou; Jiping Liu; Yinan Yao; Juehua Yu; Yuteng Weng; Min Pan; Jie Liu; Zuolin Wang; Yao Sun; Yi Eve Sun
Journal:  Protein Cell       Date:  2017-08-18       Impact factor: 14.870

7.  Pharmacokinetics, Tissue Distribution and Excretion of a Novel Diuretic (PU-48) in Rats.

Authors:  Zhi-Yuan Zhang; Hua Zhang; Dan Liu; Ying-Yuan Lu; Xin Wang; Pu Li; Ya-Qing Lou; Bao-Xue Yang; Ya-Xin Lou; Chuang Lu; Qiang Zhang; Guo-Liang Zhang
Journal:  Pharmaceutics       Date:  2018-08-08       Impact factor: 6.321

Review 8.  Breaching the Blood-Brain Tumor Barrier for Tumor Therapy.

Authors:  Fabrizio Marcucci; Angelo Corti; Andrés J M Ferreri
Journal:  Cancers (Basel)       Date:  2021-05-15       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.